secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001493152-24-043249
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma closes $4.5M public offering of stock and warrants for clinical trials
--------------------------------------------------------------------------------

- Gross proceeds of ~$4.5M from 395,574 shares, 2.55M pre-funded warrants, 2.95M common warrants at $1.525/unit.
- Proceeds primarily for IND-enabling and Phase I/II trials, including $2.3M to Theradex for Ropidoxuridine Phase II.
- Common warrants exercisable at $1.40 per share, 5-year term; pre-funded warrants at $0.001 per share.
- Placement agents A.G.P./Alliance Global Partners and Boustead Securities, with 9% aggregate cash fee.
- Post-closing shares outstanding: 3,341,673 (excluding warrants).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224043249/0001493152-24-043249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224043249/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer